AAAAAA
Results:
1-14
|
Results: 14
Authors:
Overwijk, WW
Restifo, NP
Citation: Ww. Overwijk et Np. Restifo, Creating therapeutic cancer vaccines: notes from the battlefield, TRENDS IMMU, 22(1), 2001, pp. 5-7
Authors:
Kershaw, MH
Hsu, C
Mondesire, W
Parker, LL
Wang, G
Overwijk, WW
Lapointe, R
Yang, JC
Wang, RF
Restifo, NP
Hwu, P
Citation: Mh. Kershaw et al., Immunization against endogenous retroviral tumor-associated antigens, CANCER RES, 61(21), 2001, pp. 7920-7924
Authors:
Zoeteweij, JP
Moses, AV
Rinderknecht, AS
Davis, DA
Overwijk, WW
Yarchoan, R
Orenstein, JM
Blauvelt, A
Citation: Jp. Zoeteweij et al., Targeted inhibition of calcineurin signaling blocks calcium-dependent reactivation of Kaposi sarcoma-associated herpesvirus, BLOOD, 97(8), 2001, pp. 2374-2380
Authors:
Overwijk, WW
Theoret, MR
Restifo, NP
Citation: Ww. Overwijk et al., The future of interleukin-2: Enhancing therapeutic anticancer vaccines, CA J SCI AM, 6, 2000, pp. S76-S80
Authors:
Lee, K
Overwijk, WW
O'Toole, M
Swiniarski, H
Restifo, NP
Dorner, AJ
Wolf, SF
Sturmhoefel, K
Citation: K. Lee et al., Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses, J INTERF CY, 20(6), 2000, pp. 589-596
Authors:
Overwijk, WW
Restifo, NP
Citation: Ww. Overwijk et Np. Restifo, Autoimmunity and the immunotherapy of cancer: Targeting the "self" to destroy the "other", CR R IMMUN, 20(6), 2000, pp. 433-450
Authors:
Xiang, R
Lode, HN
Chao, TH
Ruehlmann, JM
Dolman, CS
Rodriguez, F
Whitton, JL
Overwijk, WW
Restifo, NP
Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma (vol. 97, pg. 5492, 2000), P NAS US, 97(23), 2000, pp. 12932-12932
Authors:
Xiang, R
Lode, HN
Chao, TH
Ruehlmann, JM
Dolman, CS
Rodriguez, F
Whitton, JL
Overwijk, WW
Restifo, NP
Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma, P NAS US, 97(10), 2000, pp. 5492-5497
Authors:
Surman, DR
Dudley, ME
Overwijk, WW
Restifo, NP
Citation: Dr. Surman et al., CD4(+) T cell control of CD8(+) T cell reactivity to a model tumor antigen, J IMMUNOL, 164(2), 2000, pp. 562-565
Authors:
Colella, TA
Bullock, TNJ
Russell, LB
Mullins, DW
Overwijk, WW
Luckey, CJ
Pierce, RA
Restifo, NP
Engelhard, VH
Citation: Ta. Colella et al., Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy, J EXP MED, 191(7), 2000, pp. 1221-1231
Authors:
Bronte, V
Apolloni, E
Ronca, R
Zamboni, P
Overwijk, WW
Surman, DR
Restifo, NP
Zanovello, P
Citation: V. Bronte et al., Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo, CANCER RES, 60(2), 2000, pp. 253-258
Authors:
Overwijk, WW
Restifo, NP
Citation: Ww. Overwijk et Np. Restifo, Peptide vaccines for the treatment of melanoma, MED INTEL U, 24, 2000, pp. 190-199
Authors:
Overwijk, WW
Lee, DS
Surman, DR
Irvine, KR
Touloukian, CE
Chan, CC
Carroll, MW
Moss, B
Rosenberg, SA
Restifo, NP
Citation: Ww. Overwijk et al., Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes, P NAS US, 96(6), 1999, pp. 2982-2987
Authors:
Carroll, MW
Overwijk, WW
Surman, DR
Tsung, K
Moss, B
Restifo, NP
Citation: Mw. Carroll et al., Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen, J NAT CANC, 90(24), 1998, pp. 1881-1887
Risultati:
1-14
|